Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 4,628 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Single Dose Placebo Clear all

Conditions: Diffuse Cutaneous Systemic Sclerosis
Interventions: TEPEZZA, Placebo; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Los Angeles, California • New Haven, Connecticut • Baltimore, Maryland + 3 more

Conditions: Healthy Participants Study
Interventions: PRX019, Placebo; Drug
Lead sponsor: Prothena Biosciences Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Los Alamitos, California

Conditions: Differentiated Thyroid Cancer
Interventions: Selumetinib, Placebo, Radioactive Iodine Therapy; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 15
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 10 more

Conditions: Stroke
Interventions: Ranitidine, Placebo, Advanced notification, No advanced notification; Drug · Other
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Healthy Volunteers
Interventions: TAK-418, TAK-418 Matching Placebo; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Glendale, California • Salt Lake City, Utah

Conditions: Healthy Volunteers
Interventions: MAS825, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Tempe, Arizona • Overland Park, Kansas

Conditions: Healthy
Interventions: ExPEC4V, Placebo; Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Wichita, Kansas • Knoxville, Tennessee

Conditions: Healthy
Interventions: CD388 Injection, Saline placebo; Combination Product · Drug
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: COVID-19, SARS-COV-2 Infection
Interventions: BNT162b2 Vaccine, Placebo; Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 50 Years to 64 Years
Enrollment: 5,240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 196
States / cities: Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 148 more

Conditions: Healthy Volunteers - Male and Female
Interventions: KP-001, Moxifloxacin 400 mg, Placebo; Drug
Lead sponsor: Kaken Pharmaceutical; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Glendale, California

Conditions: Vomiting in Infants and/or Children, Nausea, Hematopoietic System--Cancer, Oncology
Interventions: Olanzapine, Placebo Oral Tablet; Drug
Lead sponsor: The Hospital for Sick Children; Other
Eligibility: 30 Months to 18 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 5
States / cities: San Francisco, California • Kansas City, Missouri • Chapel Hill, North Carolina + 2 more

Conditions: Prostate Cancer
Interventions: AR Antagonist (BMS-641988); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: Baltimore, Maryland • New York, New York • Madison, Wisconsin

Conditions: Respiratory Distress Syndrome, Adult
Interventions: Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells, Plasma-Lyte A; Biological
Lead sponsor: Michael A. Matthay; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 6
States / cities: San Francisco, California • Stanford, California • Boston, Massachusetts + 3 more

Conditions: Healthy, no Evidence of Disease
Interventions: Bowman-Birk inhibitor concentrate, placebo, pharmacological study, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: JNJ-26366821, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Amyotrophic Lateral Sclerosis
Interventions: DNL747, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Orlando, Florida • Salt Lake City, Utah

Conditions: Healthy Volunteers
Interventions: Ziresovir 125 mg, Ziresovir 500 mg, Placebo, Moxifloxacin hydrochloride tablet 400 mg; Drug
Lead sponsor: Shanghai Ark Biopharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Glendale, California

Conditions: Diabetes Mellitus, Ischemic Heart Disease
Interventions: 100 million Allogeneic Mesenchymal Human Stem Cells, Placebo; Drug · Other
Lead sponsor: Joshua M Hare; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Growth Hormone, Amino Acid
Interventions: Amino acid supplement, Placebo; Drug
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Asthma
Interventions: Dupilumab, Placebo, Inhaled corticosteroid (ICS) therapy, Albuterol/Salbutamol, Levalbuterol/Levosalbutamol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 1,902 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 116
States / cities: Birmingham, Alabama • Flagstaff, Arizona • Gilbert, Arizona + 100 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK2838232 PIB, GSK2838232 IR1, GSK2838232 IR2, Placebo PIB, Ritonavir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Stable Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions: CMX-2043, Placebo control; Drug
Lead sponsor: Ischemix, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Worcester, Massachusetts • Durham, North Carolina

Conditions: Orthostatic Hypotension, Pure Autonomic Failure, Multiple System Atrophy, Autonomic Failure
Interventions: Abdominal compression, Sham abdominal compression, Placebo pill, midodrine; Other · Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Dental Caries
Interventions: C16G2 Rinse, Placebo, C16G2 Gel; Drug
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 2
States / cities: Kalispell, Montana • Salt Lake City, Utah

Search by objective public record fields.

A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Phase 1 Study of PRX019 in Healthy Adult Volunteers

Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer

Extending Acute Stroke Trials to the Aerial Inter-hospital Transfer Setting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418 in Healthy Female Participants

A First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers

A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older

Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

A Study to Evaluate the Effects of KP-001 on the QT/QTc Intervals in Healthy Adults

RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy

A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer

Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)

Bowman-Birk Inhibitor Concentrate in Healthy Men

A Study of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Participants

Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis

Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects

Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)

Single Low-Dose of Supplement Amino Acid

Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)

Single and Repeated Dose Escalation Study of GSK2838232

Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy

Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure

Phase 2, Safety & Microbiology Study of C16G2 in Multiple Oral Gel &/or Mouth Rinse Doses to Healthy Adults